Abstract
Yemenite Jews in Israel are a distinctive ethnic division of the Jewish diaspora. Clinical findings, disease course and genetic tests for the LRRK2 6055G > A (G2019S) mutation were compared between Ashkenazi and Yemenite Israeli patients with Parkinson’s disease (PD). Age of onset was significantly younger in the Yemenites (P < 0.001). There were no differences in the distribution of initial symptoms, environmental risk factors or rate of motor/non-motor phenomena. The Yemenite group had a more severe disease (P < 0.001), and a more rapid disease course (P = 0.006). The frequency of Lrrk2 substitution was 12.7% in the Ashkenazi group and was not observed in the Yemenites. These results show that there are differences between Israeli Jewish ethnic groups in the severity and progression of PD, but not in clinical symptoms. The high frequency of Lrrk2 G2019S in the Ashkenazi and its absence in the Yemenite Jews suggests a specific ancestral pattern of inheritance in Ashkenazi Jews.
Similar content being viewed by others
References
Benmoyal-Segal L, Soreq H (2006) Gene-environment interactions in sporadic Parkinson’s disease. J Neurochem 97:1740–1755
Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67:1786–1791
Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 251:102–106
Djarmati A, Hedrich K, Svetel M, Schäfer N, Juric V, Vukosavic S, Hering R, Riess O, Romac S, Klein C, Kostic V (2004) Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients. Hum Mutat 23:525
Eastjam JH, Lacro JP, Jeste DV (1996) Ethnicity and movement disorders. Mt Sinai J Med 63:314–319
Goldberg-Stern H, Djaldetti R, Melamed E, Machado-Joseph Gadoth N (1994) (Azorean) disease in a Yemenite Jewish family in Israel. Neurology 44:1298–1231
Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ (1999) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology 20:239–247
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181–184
Inzelberg R, Schecthman E, Paleacu D, Zach L, Bonwitt R, Carasso RL, Nisipeanu P (2004) Onset and progression of disease in familial and sporadic Parkinson’s disease. Am J Med Genet A 124:255–258
Kamel F, Tanner C, Umbach D et al (2007) Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165:364–374
Kessler I (1972) Epidemiologic studies of Parkinson’s disease: iii. A community-based survey. Am J Epidemiol 96:242–254
Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett 221:202–204
Li X, Kitami T, Wang M, Mizuno Y, Hattori N (2005) Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/1272 of the parkin gene in sporadic Parkinson’s disease. Parkinsonism Relat Disord 11:485–491
Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, Cote L, Mayeux R (1998) Environmental risk factors for Parkinson’s disease in an urban multiethnic community. Neurology 50:279–281
Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang MX, Lantigua R, Wilder D, Gurland B et al (1995) The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 142:820–827
Mereu GP, Pacitti C, Argiolas A (1983) Effect of (−)-cathinone, a khat leaf constituent, on dopaminergic firing and dopamine metabolism in the rat brain. Life Sci 21(32)1383–1389
Nielsen JA (1985) Cathinone affects dopamine and 5-hydroxytryptamine neurons in vivo as measured by changes in metabolites and synthesis in four forebrain regions in the rat. Neuropharmacology 24:845–852
Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69:1595–1602
Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 354:424–425
Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR (2002) Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 59:1787–1792
Schoenberg BS, Osuntokun BO, Adeuja AO, Bademosi O, Nottidge V, Anderson DW, Haerer AF (1988) Comparison of the prevalence of Parkinson’s disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology 38:645–646
Schulte PA, Burnett CA, Boeniger MF, Johnson J (1996) Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am J Public Health 86:1281–1288
Semchuk KM, Love EJ, Lee RG (1992) Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 42:1328–1335
Tan EK, Tan C, Zhao Y, Yew K, Shen H, Chandran VR, Teoh ML, Yih Y, Pavanni R, Wong MC (2004a) Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity. Neurosci Lett 367:109–112
Tan LC, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, Tan AK, Saw SM (2004b) Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 62:1999–2004
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022
van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM (2003) Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 72:804–811
Wermuth L, Bünger N, Von Weitzel-Mudersback P, Pakkenberg H, Jeune B (2004) Clinical characteristics of Parkinson’s disease among Inuit Greenland and inhabitants of the Faroe Islands and Als (Denmark). Mov Disord 19:821–824
Willis AS, Freeman ML, Summar SR, Barr FE, Williams SM, Dawson E, Summar ML (2003) Ethnic diversity in a critical gene responsible for glutathione synthesis. Free Rad Biol Med 34:72–76
Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758
Zhang ZX, Román GC (1993) Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 12:195–208
Acknowledgments
This study was supported by the National Parkinson Foundation, USA, and the Alan and Norma Aufzien Chair for Research in Parkinson’s Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Molecular genetic analysis was supported by the Neurogenetic Core of a Morris K. Udall Center (NINDS P50 NS40256).
Conflicts of interest statement
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Djaldetti, R., Hassin-Baer, S., Farrer, M.J. et al. Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel. J Neural Transm 115, 1279–1284 (2008). https://doi.org/10.1007/s00702-008-0074-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-008-0074-z